Abstract
Most depressed patients suffer from sleep abnormalities, which are one of the critical symptoms of depression. They are robust risk factors for the initiation and development of depression. Studies about sleep electroencephalograms have shown characteristic changes in depression such as reductions in non-rapid eye movement sleep production, disruptions of sleep continuity and disinhibition of rapid eye movement (REM) sleep. REM sleep alterations include a decrease in REM sleep latency, an increase in REM sleep duration and REM sleep density with respect to depressive episodes. Emotional brain processing dependent on the normal sleep-wake regulation seems to be failed in depression, which also promotes the development of clinical depression. Also, REM sleep alterations have been considered as biomarkers of depression. The disturbances of norepinephrine and serotonin systems may contribute to REM sleep abnormalities in depression. Lastly, this review also discusses the effects of different antidepressants on REM sleep disturbances in depression.
Keywords: Antidepressants, depression, mood disorders, norepinephrine, serotonin, sleep disorders.
Graphical Abstract
Current Neuropharmacology
Title:The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression
Volume: 13 Issue: 4
Author(s): Yi-Qun Wang, Rui Li, Meng-Qi Zhang, Ze Zhang, Wei-Min Qu and Zhi-Li Huang
Affiliation:
Keywords: Antidepressants, depression, mood disorders, norepinephrine, serotonin, sleep disorders.
Abstract: Most depressed patients suffer from sleep abnormalities, which are one of the critical symptoms of depression. They are robust risk factors for the initiation and development of depression. Studies about sleep electroencephalograms have shown characteristic changes in depression such as reductions in non-rapid eye movement sleep production, disruptions of sleep continuity and disinhibition of rapid eye movement (REM) sleep. REM sleep alterations include a decrease in REM sleep latency, an increase in REM sleep duration and REM sleep density with respect to depressive episodes. Emotional brain processing dependent on the normal sleep-wake regulation seems to be failed in depression, which also promotes the development of clinical depression. Also, REM sleep alterations have been considered as biomarkers of depression. The disturbances of norepinephrine and serotonin systems may contribute to REM sleep abnormalities in depression. Lastly, this review also discusses the effects of different antidepressants on REM sleep disturbances in depression.
Export Options
About this article
Cite this article as:
Wang Yi-Qun, Li Rui, Zhang Meng-Qi, Zhang Ze, Qu Wei-Min and Huang Zhi-Li, The Neurobiological Mechanisms and Treatments of REM Sleep Disturbances in Depression, Current Neuropharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570159X13666150310002540
DOI https://dx.doi.org/10.2174/1570159X13666150310002540 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion
Current Alzheimer Research Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry APOE Genotypes and Brain Imaging Classes in Normal Cognition, Mild Cognitive Impairment, and Alzheimer’s Disease: A Longitudinal Study
Current Alzheimer Research Cellular and Molecular Mechanisms of Dementia: Decoding the Causal link of Diabetes Mellitus in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer’s Disease
Current Medicinal Chemistry Perspectives on Brain-Targeting Drug Delivery Systems
Current Pharmaceutical Biotechnology Plasma Steroid Level Measured Using Modern Separation Techniques as Biomarkers in Biological Diagnostics
Current Pharmaceutical Analysis Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Editorial: Advances in the Treatment of Neurodegenerative Diseases and Epilepsy
Current Pharmaceutical Design Platelet Function Testing in Atherothrombotic Disease
Current Pharmaceutical Design Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Inaccuracy in Clinical Trials: Effects and Methods to Control Inaccuracy
Current Alzheimer Research Emerging Risk Factors for Dementia: The Role of Blood Pressure Variability
CNS & Neurological Disorders - Drug Targets Neuronal-glial Interactions Define the Role of Nitric Oxide in Neural Functional Processes
Current Neuropharmacology Association between <i>Toxoplasma gondii</i> Infection and Headache: A Systematic Review and Meta-Analysis
Infectious Disorders - Drug Targets Hippocampal Morphology and Autobiographic Memory in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease?
Current Alzheimer Research